Design, Development and Evaluation of Gliclazide Tablets for Non-Insulin Dependent Diabetes Mellitus
The goal of the present work was to formulate the oral tablets of gliclazide for non-insulin dependent diabetes and provide a dosage form for prolonged period of time, in order to improve efficacy, reduce the frequency of total dose and better patient compliance. The powders were evaluated for angle of repose, bulk density, compressibility index and hausner’s ratio. All the tests revealed that powders showed excellent flow properties. The resulting tablets were evaluated for thickness, diameter, and uniformity of weight test, hardness, friability and drug content. In-vitro release of drug was performed using 7.4 pH phosphate buffers and dissolution was done. All the tablet formulations showed acceptable pharmacological properties and complied with pharmacopoeias standards.
2. Walker R., C. Edwards, “Diabetes Mellitus”, Chapter 43 in Clinical pharmacy and Therapeutic, 2nd edition, Churchill Livingstone: 633-637.
3. Rathbone M.J., G. Ponchel, F.A. Ghazali“Systemic Oral Mucosal Drug Delivery and Delivery Systems”, Chapter 11 in Oral Mucosal Drug Delivery, Marcel Dekker,2010; 63:243-245.
4. Zhang H. J.R. Robinson, “Routtes of Drug Transport Across Oral Mucosa”. Chapter 3 in Oral Mucosal Drug Delivery, Marcel Dekker, 2012; 63:52-53.
5. KellawayI.W. ,S.J. Warren. “Mucoadhesive hydrogels for Buccal Delivery”, Chapter 10 in Oral Mucosal Drug Delivery, Marcel Dekker, 63:231-232.
6. Perioli L, Ambrogi V, Giovagnoli S, Blassi P, Rossi C, Mucoadhesivebilayered tablets For buccal sustained release of flurbiprofen, AAPS Pharm Sci Tech,2007; 8(3):54.
7. AndrzejCzyrski, MatyldaResztak, Tadeusz Hermann Determination of Gliclazide Minimum Concentration in Type 2 Diabetes Mellitus Patients 2018 ;106:1267-1270.
8. Arti Banerjee , P R P Verma, Subhash Gore Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide 2015 ;16(3):554-68
9. Jamadar, Snehal P. Mulye, Poonam S. Karekar , Yogesh V, Pore, Kishor B and Burade.Development and validation of UV spectrophotometric method for the determination of gliclazide in tablet dosage form, Der Pharma Chemica, 2011; 3(4):38-343.
10. SeemaPushkar and Nikhil K. Sachan. Pharmaceutical characterization and assessment of drug release behaviour of diclofenac sodium extended release matrix devices, Int. J. Pharm. Sci. Tech., 2009; 2(1):14-21.
11. Shalin A. Modi, Gaikwad P.D., Bankar V.H. and Pawar S.P. Sustained release drug delivery system: A Review, International Journal of Pharma Research and Development, 2011; 2(12):147-160.
12. Sundaramoorthy K., Kavimani S. and Swaminathan S. Development and evaluation of extended release metformin hydrochloride matrix tablets: Rate of In-Vitro and In-Vivo Release Studies, Journal of Pharmacy Research, 2011; 4(3):884-885.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).